These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 31093928)

  • 1. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.
    Hulin A; Stocco J; Bouattour M
    Clin Pharmacokinet; 2019 Aug; 58(8):983-1014. PubMed ID: 31093928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
    Sato Y; Nishiofuku H; Yasumoto T; Nakatsuka A; Matsuo K; Kodama Y; Okubo H; Abo D; Takaki H; Inaba Y; Yamakado K
    J Vasc Interv Radiol; 2018 Aug; 29(8):1061-1067. PubMed ID: 29934260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching.
    Kaplan DE; Mehta R; D'Addeo K; Gade TP; Taddei TH
    J Vasc Interv Radiol; 2018 Apr; 29(4):540-549.e4. PubMed ID: 29477619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
    Parvinian A; Casadaban LC; Hauck ZZ; van Breemen RB; Gaba RC
    Diagn Interv Radiol; 2015; 21(3):235-40. PubMed ID: 25835078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
    Lencioni R
    Crit Rev Oncol Hematol; 2012 Aug; 83(2):216-24. PubMed ID: 22142656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
    Kim GM; Kim MD; Kim do Y; Kim SH; Won JY; Park SI; Lee do Y; Shin W; Shin M
    J Vasc Interv Radiol; 2016 Jul; 27(7):1086-92. PubMed ID: 27179404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
    Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
    da Fonseca LG; Reig M; Bruix J
    Clin Liver Dis; 2020 Nov; 24(4):719-737. PubMed ID: 33012455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).
    Kudo M; Arizumi T
    Oncology; 2017; 93 Suppl 1():127-134. PubMed ID: 29258086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
    Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
    World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.
    Kudo M
    World J Gastroenterol; 2019 Feb; 25(7):789-807. PubMed ID: 30809080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
    Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
    Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
    Weintraub JL; Salem R
    J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study.
    Chatziioannou AN; Siskos AP; Loxas D; Kavatzas N; Agrogiannis G; Fokas D; Malagari K; Kostomitsopoulos NG; Tsigkou O; Tamvakopoulos C
    J Vasc Interv Radiol; 2013 Nov; 24(11):1657-63.e1. PubMed ID: 24060438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
    Zhang Y; Fan W; Wang Y; Lu L; Fu S; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2015 Dec; 20(12):1417-24. PubMed ID: 26446238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma.
    Facciorusso A; Mariani L; Sposito C; Spreafico C; Bongini M; Morosi C; Cascella T; Marchianò A; Camerini T; Bhoori S; Brunero F; Barone M; Mazzaferro V
    J Gastroenterol Hepatol; 2016 Mar; 31(3):645-53. PubMed ID: 26331807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
    Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.